OverviewSuggest Edit

Polyneuron is a pharmaceutical company that is committed to the development of a new drug class for the treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. The Company’s Antibody-Catch™ technology platform enables the chemical design of injectable glycopolymers that are able to selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact.

HQBasel, CH

Latest Updates

Employees (est.) (Jul 2021)17(+7%)
Cybersecurity ratingBMore

Key People/Management at Polyneuron

Ruben Herrendorff

Ruben Herrendorff

Co-Founder & CEO
Barker M.D.

Barker M.D.

Pascal Haenggi

Pascal Haenggi

Co-Founder & CSO
Aled Williams

Aled Williams

Pascal Hänggi

Pascal Hänggi

co-founder and Chief Scientific Officer
Show more

Polyneuron Office Locations

Polyneuron has an office in Basel
Basel, CH (HQ)
Hochbergerstrasse 60C
Show all (1)

Polyneuron Financials and Metrics

Summary Metrics

Founding Date


Polyneuron total Funding

$44.3 m

Polyneuron latest funding size

$15.33 m

Time since last funding

10 months ago

Polyneuron investors

Polyneuron's latest funding round in September 2020 was reported to be $15.3 m. In total, Polyneuron has raised $44.3 m
Show all financial metrics

Polyneuron Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Polyneuron Online and Social Media Presence

Embed Graph

Polyneuron Blogs

Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants

Polyneuron is proud to announce that – together with the University of Basel – we awarded grant of CHF 1.2M to advance novel treatments to support ABO-Incompatible transplants. Press Release

Polyneuron appoints Aled Williams as chief business officer

We are extremely pleased to welcome Aled Williams to Polyneuron as our new Chief Business Officer. Aled brings more than 25 years’ of leadership experience across both pharmaceutical and biotech sectors. Press Release

Polyneuron extends Series A to CHF 36.5 million

Polyneuron announces a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors. Press…

Polyneuron’s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy

Polyneuron is proud to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN‑1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of…

Polyneuron announces appointment of chief medical officer

We are extremely pleased to welcome Dr Debra Barker to Polyneuron as our new chief medical officer. Dr Barker has a successful track record in drug development spanning over 25 years, involving many successful drug approvals. Press Release

Polyneuron Frequently Asked Questions

  • When was Polyneuron founded?

    Polyneuron was founded in 2014.

  • Who are Polyneuron key executives?

    Polyneuron's key executives are Ruben Herrendorff, Barker M.D. and Pascal Haenggi.

  • How many employees does Polyneuron have?

    Polyneuron has 17 employees.

  • Who are Polyneuron competitors?

    Competitors of Polyneuron include ReViral, Sosei Heptares and Seres Therapeutics.

  • Where is Polyneuron headquarters?

    Polyneuron headquarters is located at Hochbergerstrasse 60C, Basel.

  • Where are Polyneuron offices?

    Polyneuron has an office in Basel.

  • How many offices does Polyneuron have?

    Polyneuron has 1 office.